Dr. Öğr. Üyesi TOLGA SÜTLÜ | AVESİS

Akademik Veri Yönetim Sistemi

Yayınlar & Eserler

Makaleler 33

1. CD28 signaling domain boosts persistence and in vivo anti-tumor activity of stem cell-derived CD19-CAR-NK cells

Kok N., Ozkazanc D., van Vliet A. A., Steenmans D., Singh S. P., SÜTLÜ T., et al.

iScience , cilt.28, sa.6, 2025 (SCI-Expanded, Scopus)

2. TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer

Karahan Z. S., Aras M., Sutlu T.

TURKISH JOURNAL OF HEMATOLOGY , cilt.40, sa.1, ss.1-10, 2023 (SCI-Expanded, Scopus, TRDizin)

3. Human immunodeficiency virus type 1 impairs sumoylation

Mete B., Pekbilir E., Bilge B. N., Georgiadou P., Celik E., Sutlu T., et al.

LIFE SCIENCE ALLIANCE , cilt.5, sa.6, 2022 (SCI-Expanded, Scopus)

4. Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma

Nahi H., Chrobok M., Meinke S., Gran C., Marquardt N., Afram G., et al.

CELL REPORTS MEDICINE , cilt.3, sa.2, 2022 (SCI-Expanded, Scopus)

5. Decline of humoral immune responses after natural SARS-CoV-2 infection can be efficiently reversed by vaccination

ÖKTELİK F. B., YILMAZ V., GELMEZ M. Y., AKDENİZ N., Pamukcu C., Sutlu T., et al.

CANADIAN JOURNAL OF MICROBIOLOGY , cilt.68, ss.543-550, 2022 (SCI-Expanded, Scopus)

6. Development of a pseudovirus-based assay for analysis of neutralizing activity against SARS-CoV-2 in convalescent plasma

Aras M., Pamukcu C., Celik E., Ergun E. Z., Karahan Z. S., Turkoz G., et al.

EUROPEAN JOURNAL OF IMMUNOLOGY , ss.368, 2021 (SCI-Expanded, Scopus)

7. A colorimetric pseudovirus-based assay using secreted embryonic alkaline phosphatase for analysis of neutralizing activity against SARS-CoV-2

Pamukcu C., Aras M., Celik E., Ergun E. Z., Karahan Z. S., Sutlu T.

EUROPEAN JOURNAL OF IMMUNOLOGY , ss.112, 2021 (SCI-Expanded, Scopus)

8. Characterization of zika virus infection of human fetal cardiac mesenchymal stromal cells

Rossi F., Josey B., Sayitoglu E. C., Potens R., Sultu T., Duru A. D., et al.

PLOS ONE , cilt.15, sa.9, 2020 (SCI-Expanded, Scopus)

9. Engineering antigen-specific natural killer cells against the melanoma-associated antigen tyrosinase via TCR gene transfer.

Parlar A., Sayitoglu E. C., Pamukcu C., Georgoudaki A., Ozkazanc D., Aras M., et al.

CANCER IMMUNOLOGY RESEARCH , sa.4, ss.49-50, 2020 (SCI-Expanded, Scopus)

10. Natural killer cells genetically modified to overexpress DNAM-1 exert enhanced antitumor responses against CD112/CD155+sarcomas and other malignancies.

Sayitoglu E. C., Chrobok M., Georgoudaki A., Josey B. J., Hartman M., Vallabhaneni E., et al.

CANCER IMMUNOLOGY RESEARCH , sa.4, ss.64-65, 2020 (SCI-Expanded, Scopus)

11. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D

Sayitoglu E. C., Georgoudaki A., Chrobok M., Ozkazanc D., Josey B. J., Arif M., et al.

FRONTIERS IN IMMUNOLOGY , cilt.11, 2020 (SCI-Expanded, Scopus)

12. Myeloid maturation potentiates STAT3-mediated atypical IFN-gamma signaling and upregulation of PD-1 ligands in AML and MDS

YÖYEN ERMİŞ D., Tunali G., Tavukcuoglu E., Horzum U., Ozkazanc D., Sutlu T., et al.

SCIENTIFIC REPORTS , cilt.9, 2019 (SCI-Expanded, Scopus)

13. Plasmonic Selection of ssDNA Aptamers against Fibroblast Growth Factor Receptor

KURT H., Eyupoglu A. E., Sutlu T., Budak H., Yuce M.

ACS COMBINATORIAL SCIENCE , cilt.21, sa.8, ss.578-587, 2019 (SCI-Expanded, Scopus)

14. Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer

Parlar A., Sayitoglu E. C., Ozkazanc D., Georgoudaki A., Pamukcu C., Aras M., et al.

EUROPEAN JOURNAL OF IMMUNOLOGY , sa.8, ss.1278-1290, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

Sürdürülebilir Kalkınma

15. Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells

Chrobok M., Dahlberg C. I. M., Sayitoglu E. C., Beljanski V., Nahi H., Gilljam M., et al.

CANCERS , cilt.11, sa.1, 2019 (SCI-Expanded, Scopus)

16. Circulating LL37 targets plasma extracellular vesicles to immune cells and intensifies Behcet's disease severity

Kahraman T., Gucluler G., Simsek I., Yagci F. C., Yildirim M., ÖZEN C., et al.

JOURNAL OF EXTRACELLULAR VESICLES , cilt.6, 2017 (SCI-Expanded, Scopus)

17. Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma

Duru A. D., Sutlu T., Wallblom A., Uttervall K., Lund J., Stellan B., et al.

PLOS ONE , cilt.10, sa.9, 2015 (SCI-Expanded, Scopus)

18. Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model

Bestas B., Moreno P. M. D., Blomberg K. E. M., Mohammad D. K., Saleh A. F., Sutlu T., et al.

JOURNAL OF CLINICAL INVESTIGATION , cilt.124, sa.9, ss.4067-4081, 2014 (SCI-Expanded, Scopus)

19. In search of the molecular consequences of 8p21 deletion in multiple myeloma: commentary on Gmidene et al

Sutlu T., Alici E., Gahrton G., Nahi H.

MEDICAL ONCOLOGY , cilt.30, sa.2, 2013 (SCI-Expanded, Scopus)

20. Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene Therapy

Sutlu T., Nystrom S., Gilljam M., Stellan B., Applequist S. E., Alici E.

HUMAN GENE THERAPY , cilt.23, sa.10, ss.1090-1100, 2012 (SCI-Expanded, Scopus)

Creative Commons License

21. Clinical impact of chromosomal aberrations in multiple myeloma

Nahi H., Sutlu T., Jansson M., Alici E., Gahrton G.

JOURNAL OF INTERNAL MEDICINE , cilt.269, sa.2, ss.137-147, 2011 (SCI-Expanded, Scopus)

22. Ex vivo expansion of natural killer cells: a question of function

Sutlu T., Alici E.

CYTOTHERAPY , cilt.13, sa.6, ss.767-768, 2011 (SCI-Expanded, Scopus)

23. Constitutional inv(3) in myelodysplastic syndromes

Gahrton C., Nahi H., Jansson M., Wallblom A., Alici E., Sutlu T., et al.

LEUKEMIA RESEARCH , cilt.34, sa.12, ss.1627-1629, 2010 (SCI-Expanded, Scopus)

24. Suicide gene therapy for graft-versus-host disease

Georgoudaki A., Sutlu T., Alici E.

IMMUNOTHERAPY , cilt.2, sa.4, ss.521-537, 2010 (SCI-Expanded, Scopus)

25. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor

Sutlu T., Stellan B., Gilljam M., Quezada H. C., Nahi H., Gahrton G., et al.

CYTOTHERAPY , cilt.12, sa.8, ss.1044-1055, 2010 (SCI-Expanded, Scopus)

26. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study

Barkholt L., Alici E., Conrad R., Sutlu T., Gilljam M., Stellan B., et al.

IMMUNOTHERAPY , cilt.1, sa.5, ss.753-764, 2009 (SCI-Expanded, Scopus)

27. Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation

Paul E., Sutlu T., Deneberg S., Alici E., Bjorkstrand B., Jansson M., et al.

ONCOLOGY REPORTS , cilt.22, sa.1, ss.137-142, 2009 (SCI-Expanded, Scopus)

Creative Commons License

28. Natural killer cell-based immunotherapy in cancer: current insights and future prospects

Sutlu T., Alici E.

JOURNAL OF INTERNAL MEDICINE , cilt.266, sa.2, ss.154-181, 2009 (SCI-Expanded, Scopus)

29. The prognostic significance of 8p21 deletion in multiple myeloma

Sutlu T., Alici E., Jansson M., Wallblom A., Dilber M. S., Gahrton G., et al.

BRITISH JOURNAL OF HAEMATOLOGY , cilt.144, sa.2, ss.266-268, 2009 (SCI-Expanded, Scopus)

30. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

Alici E., Sutlu T., Boejrkstrand B., Gilljam M., Stellan B., Nahi H., et al.

BLOOD , cilt.111, sa.6, ss.3155-3162, 2008 (SCI-Expanded, Scopus)

Creative Commons License

31. Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model

Alici E., Konstantinidis K. V., Sutlu T., Aints A., Gahrton G., Ljunggren H., et al.

EXPERIMENTAL HEMATOLOGY , cilt.35, sa.12, ss.1839-1846, 2007 (SCI-Expanded, Scopus)

32. Delivery of short interfering RNA using endosomolytic cell-penetrating peptides

Lundberg P., El-Andaloussi S., Sutlu T., Johansson H., Langel U.

FASEB JOURNAL , cilt.21, sa.11, ss.2664-2671, 2007 (SCI-Expanded, Scopus)

33. Triticum durum metallothionein - Isolation of the gene and structural characterization of the protein using solution scattering and molecular modeling

Bilecen K., Ozturk U., Duru A., Sutlu T., Petoukhov M., Svergun D., et al.

JOURNAL OF BIOLOGICAL CHEMISTRY , cilt.280, sa.14, ss.13701-13711, 2005 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 13

1. STAT3-mediated atypical IFN-gamma signaling modulates the PD-1 ligands in CD11b-positive subpopulation of MDS and AML cells

YÖYEN ERMİŞ D., Tunali G., Tavukcuoglu E., Ozkazanc D., Sutlu T., BÜYÜKAŞIK Y., et al.

17th International Congress of Immunology of the International-Union-of-Immunological-Societies (IUIS), Beijing, Çin, 19 - 23 Ekim 2019, ss.90, (Özet Bildiri)

2. Identification and strategic targeting of key anti-viral defense mechanisms in Natural Killer cells

Sayitoglu E. C., Ozkazanc D., Sarac A., Parlar A., Alici E., ERMAN M. B., et al.

Annual Meeting of the American-Association-of-Immunologists (AAI), Texas, Amerika Birleşik Devletleri, 4 - 08 Mayıs 2018, (Özet Bildiri)

3. Engineering antigen-specific NK cells via TCR gene transfer: A novel source for adoptive immunotherapy

Parlar A., Pamukcu C., Ozkazanc D., Aras M., Dahlberg C., Chrobok M., et al.

European-Society-of-Gene-and-Cell-Therapy (ESCGT) Congress, Berlin, Almanya, 01 Ocak 2017, (Özet Bildiri)

4. Adaption of NK-92 cells to serum-free culture with inherent anti-tumor response: NK-92 cells stand strong in a serum-free milieu

Chrobok M., Dahlberg C. I. M., Sayitoglu C., Nahi H., Sarhan D., Gilljam M., et al.

44th Annual Meeting of the Scandinavian-Society-for-Immunology (SSI), Stockholm, İsveç, 17 - 20 Ekim 2017, ss.342, (Özet Bildiri)

5. Optimized genetic modification of primary human NK cells

Wagner A. K., Chrobok M., Hussain A., Gilljam M., Dahlberg C. I. M., Sutlu T., et al.

44th Annual Meeting of the Scandinavian-Society-for-Immunology (SSI), Stockholm, İsveç, 17 - 20 Ekim 2017, ss.348, (Özet Bildiri)

6. Innate immune sensors restrict lentiviral gene delivery to human natural killer cells: novel perspectives on the use of viral vectors

Sayitoglu E. C., Duru A. D., Chrobok M., Chiang C., Parlar A., Senturk G. H., et al.

Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy (ESGCT) and Finnish-Society-of-Gene-Therapy (FSGT), Helsinki, Finlandiya, 17 - 20 Eylül 2015, (Özet Bildiri)

7. Multiple Myeloma patients with del(8)(p21) are more resistant to Bortezomib treatment

Duru A. D., Sutlu T., Wallblom A., Uttervall K., Lund J., Stellan B., et al.

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, (Özet Bildiri)

8. Personalized therapy for X-linked agammaglobulinemia (XLA) by oligonucleotide-induced splice-correction

Bestas B., Moreno P. M. D., Blomberg K. E. M., Mohammad D. K., Saleh A. F., Sutlu T., et al.

ESGCT and NVGCT Collaborative Congress, The Hague, Hollanda, 23 - 26 Ekim 2014, (Özet Bildiri)

9. Enhancement of lentiviral transduction efficiency by inhibition of intracellular anti-viral defense mechanisms

Sutlu T., Nystrom S., Gilljam M., Stellan B., Applequist S. E., Alici E.

Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy, Versailles, Fransa, 25 - 29 Ekim 2012, (Özet Bildiri)

10. RNA THERAPEUTICS IN XLA - A NOVEL STRATEGY TO REPAIR BTK MUTATIONS

Bestas B., Moreno P. M., Blomberg K. E. M., Berglof A., Gustafsson M. O., Mohammad D. K., et al.

15th Biennial Meeting European-Society-for-Immunodeficiency (ESID), Florence, İtalya, 3 - 06 Ekim 2012, ss.165-166, (Özet Bildiri)

11. Expansion of NK cells for cancer immunotherapy: from process optimization to clinical evaluation

Sutlu T., Gahrton G., Alici E.

18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, İtalya, 22 - 25 Ekim 2010, ss.1416, (Özet Bildiri)

12. Ex vivo expanded autologous natural killer cells as a novel therapeutic approach in multiple myeloma

Alici E., Sutlu T., Bjokstrand B., Gilljam M., Stellan B., Nahi H., et al.

16th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Brugge, Belçika, 13 - 16 Kasım 2008, ss.1183, (Özet Bildiri)

13. Natural killer cells kill syngeneic myeloma cells in C57Bl/KaLwRij upon adoptive transfer

Alici E., Sutlu T., Gahrton G., Dilber S.

15th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Rotterdam, Hollanda, 27 - 30 Ekim 2007, ss.992-993, (Özet Bildiri)

Metrikler

Yayın

46

Yayın (WoS)

46

Yayın (Scopus)

33

Atıf (WoS)

326

H-İndeks (WoS)

10

Atıf (Scopus)

1447

H-İndeks (Scopus)

16

Atıf (Scholar)

788

H-İndeks (Scholar)

11

Atıf (Sobiad)

10

H-İndeks (Sobiad)

2

Proje

12

Fikri Mülkiyet

2

Tez Danışmanlığı

14

Açık Erişim

3

BM Sürdürülebilir Kalkınma Amaçları